Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Shanghai Aucta Pharmaceuticals Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners, both of whom are located within 1 distinct art unit. This indicates a centralized examination process where different examiners are applying the standards of a single art unit. The focus on 1 distinct art unit allows for a predictable prosecution environment compared to portfolios spread across multiple units.
MOU, LIYUAN is the busiest examiner for the portfolio, with 1 pending office action. Given the total of 2 pending actions, the workload is divided among the examiners. This structure requires the company to manage the pending office actions by addressing the specific feedback of 2 distinct examiners. However, because both examiners are in the same art unit, practitioners can likely apply a consistent legal strategy across both of the pending actions. This centralized approach is beneficial for maintaining a uniform prosecution history within the Biotechnology & Pharmaceuticals technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19033064 | A PHARMACEUTICAL KIT FOR PREPARATION OF READY-TO-USE VIGABATRIN SOLUTION | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19033064 | A PHARMACEUTICAL KIT FOR PREPARATION OF READY-TO-USE VIGABATRIN SOLUTION | MOU, LIYUAN | — |
| 18779285 | LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF | TRAN, SUSAN T | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19033064 | A PHARMACEUTICAL KIT FOR PREPARATION OF READY-TO-USE VIGABATRIN SOLUTION | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | — | Pending | Jan 21, 2025 |
| 18779285 | LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF | TRAN, SUSAN T | — | §102Other | Non-Final OA | — | Pending | Jul 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial